Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
The proteasome has emerged as a novel target for antineoplastic treatment of hematological malignancies and solid tumors, including those of the central nervous system. To identify cell death pathways activated in response to inhibition of the proteasome system in cancer cells, we treated human SH-SY5Y neuroblastoma cells with the selective proteasome inhibitor (PI) epoxomicin (Epoxo). Prolonged exposure to Epoxo was associated with increased levels of poly-ubiquitinylated proteins and p53, release of cytochrome c from the mitochondria, and activation of caspases. Analysis of global gene expression using high-density oligonucleotide microarrays revealed that Epoxo triggered transcriptional activation of the two Bcl-2-homology domain-3-only (BH3-only) genes p53 upregulated modulator of apoptosis (PUMA) and Bim. Subsequent studies in PUMA- and Bim-deficient cells indicated that Epoxo-induced caspase activation and apoptosis was predominantly PUMA-dependent. Further characterization of the transcriptional response to Epoxo in HCT116 human colon cancer cells demonstrated that PUMA induction was p53-dependent; with deficiency in either p53 or PUMA significantly protected HCT116 cells against Epoxo-induced apoptosis. Our data suggest that p53 activation and the transcriptional induction of its target gene PUMA play an important role in the sensitivity of cancer cells to apoptosis induced by proteasome inhibition, and imply that antineoplastic therapies with PIs might be especially useful in cancers with functional p53.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As proteasome inhibitors induce apoptosis in several cell lines [26–28]”
From PSMC5 insufficiency and P320R mutation impair proteasome function (2024) · cites this paper as [27]
Citations
Cites
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 1×
“NF-kB is constitutively activated in many cancer cells and is associated with cancer development and progression (Karin, 2006).”
BackgroundA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“Indeed, clinical efficiency of Bortezomib (PS-341/Velcade), a reversible PI has recently been observed in multiple myeloma patients (Richardson et al., 2003).”
BackgroundPUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315 · cited 2×
“PUMA has been identified as a key mediator of the p53dependent apoptotic response (Nakano and Vousden, 2001; Yu et al., 2001).”
BackgroundPalombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096 · cited 1×
“Indeed, the activity of several transcription factors, including p53 and nuclear factor kappa B (NF-kB) (Chowdary et al., 1994; Palombella et al., 1994), are known to be modulated by proteasome activity.”
Backgroundc-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715 · cited 1×
“The most prominently downregulated genes after proteasome inhibition were members of the c-Myc family of transcription factors which control expression of genes involved in cell growth and metabolism (Dang, 1999).”
BackgroundBouillet, P., Metcalf, D., Huang, D. C. S., Tarlinton, D. M., Kay, T. W. H., Köntgen, F., Adams, J. M., & Strasser, A. (1999) · Science · doi:10.1126/science.286.5445.1735 · Cited by 1,504 · cited 1×
“The generation of the PUMA / and Bim / mice have been described previously (Bouillet et al., 1999; Villunger et al., 2003a).”
MethodSelf-citationp53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327 · cited 3×
“Oncogene imbalance between proapoptotic and antiapoptotic Bcl-2 proteins resulting in the release of cytochrome c and apoptosis (Villunger et al., 2003a; Willis and Adams, 2005).”
BackgroundMethodSelf-citationPUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells
Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., & Vogelstein, B. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00213-1 · Cited by 1,280 · cited 3×
“PUMA has been identified as a key mediator of the p53dependent apoptotic response (Nakano and Vousden, 2001; Yu et al., 2001).”
BackgroundThe proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201 · cited 1×
“Several key regulatory proteins involved in cell proliferation and differentiation are regulated by proteasome-mediated proteolysis resulting in the activation or inhibition of specific cell signaling pathways (”
Background
Research works printed but not linked: 1
- Adams J . (2004b). The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349–360. · DOI · Paper page
Cited by
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,176
“In tumor cells with wild-type p53, however, proteasome inhibitors can instead act by driving p53-dependent expression of Puma (Concannon et al., 2006).”
BackgroundPUMA, a potent killer with or without p53
Yu, J., & Zhang, L. (2008) · Oncogene · doi:10.1038/onc.2009.45 · Cited by 554
“, 2005), and cancer cell death induced by the proteasome inhibitors MG-132, bortezomib and epoxomicin (Concannon et al., 2007; Ding et al., 2007), and by the monoflavonoid wogonin (Lee et al.”
An Epstein-Barr virus–encoded microRNA targets PUMA to promote host cell survival
Choy, E. Y.-W., Siu, K.-L., Kok, K.-H., Lung, R. W.-M., Tsang, C. M., To, K.-F., Kwong, D. L.-W., Tsao, S. W., & Jin, D.-Y. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072581 · Cited by 462
Bcl-2 family on guard at the ER
Szegezdi, E., MacDonald, D. C., Ní Chonghaile, T., Gupta, S., & Samali, A. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00612.2008 · Cited by 241
“Puma has also been shown to be required for the initiation of apoptosis in neuronal cells triggered by the abnormal accumulation of malformed proteins associated with several neurodegenerative diseases (for example, amyotrophic lateral sclerosis; 54) or as a result of disrupting cellular protein degradation pathways u…”
BackgroundDayal, S., Sparks, A., Jacob, J., Allende-Vega, N., Lane, D. P., & Saville, M. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805871200 · Cited by 199
Metadata
- Authors
- Concannon, C. G., Koehler, B. F., Reimertz, C., Murphy, B. M., Bonner, C., Thurow, N., Ward, M. W., Villunger, A., Strasser, A., Kögel, D., & Prehn, J. H. M.
- Affiliations
- Royal College of Surgeons in Ireland (IE)
- Goethe University Frankfurt (DE)
- Innsbruck Medical University (AT)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Prehn, J H M
- Venue
- Oncogene
- Published
- 2006-09-18
- Volume
- 26
- Issue
- 12
- Pages
- 1681-1692
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2056205420
- Cited by
- 95
- References
- 55
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 7 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 2 · 2014: 6 · 2013: 4 · 2012: 6
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Science Foundation Ireland
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- proteasome inhibition, apoptosis, p53, PUMA, building information modeling, BH3-only proteins, epoxomicin, caspase activation, cytochrome c release, neuroblastoma, colon cancer, transcriptional regulation, antineoplastic therapy, p53-dependent apoptosis
- MeSH terms
- Base Sequence, Humans, Molecular Sequence Data, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Apoptosis, Protein Folding, DNA Primers, Oligonucleotide Array Sequence Analysis, Cell Line, Tumor, Apoptosis Regulatory Proteins, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. https://app.cochat.ai/papers/10.1038/sj.onc.1209974
- The paper
- Concannon, C. G., Koehler, B. F., Reimertz, C., Murphy, B. M., Bonner, C., Thurow, N., Ward, M. W., Villunger, A., Strasser, A., Kögel, D., & Prehn, J. H. M. (2007). Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. Oncogene. https://doi.org/10.1038/sj.onc.1209974
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.